Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252312719 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Gaurav Baranwal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Chronic kidney disease (CKD) affects more than 10% of the world’s population. Hemodialysis, along with peritoneal dialysis and renal transplant, is one of the renal replacement therapies offered to patients with CKD/end-stage renal disease (ESRD). To proceed with hemodialysis, vascular access is required. The two means of long-term access are arteriovenous fistula (AVF) and arteriovenous graft (AVG). Multiple therapies have been created to help the long-term patency of AVFs. These therapies are needed as 40% of AVFs fail within the first year and additional intervention is required. Much of the existing research has focused on biomarkers, immune cells, hypoxia, and cell-based therapies. Regeneration therapy using mesenchymal stem cells seeks to investigate other ways that we can treat AVF failure. Mesenchymal stem cells are harvested as two main types, fetal and adult. Fetal cells are harvested at different times in fetal gestation and from multiple sources, placental blood, Whartons jelly, and amniotic stem cell fluid. Taken together, this review summarizes the different preclinical/clinical studies conducted using different types of MSCs towards vascular regenerative medicine and further highlights its potential to be a suitable alternative approach to enhance AVF patency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Gaurav Baranwal, Haseeb Mukhtar, Jamie Kane
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- NIH HHS
- NIH
- Minnesota Regenerative Medicine
Zitieren
APA
Baranwal, G., Mukhtar, H., Kane, J., Lemieux, A., & Misra, S. (2024). Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252312719
Vancouver
Baranwal G, Mukhtar H, Kane J, Lemieux A, Misra S. Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252312719
BibTeX
@article{Baranwal2024,
author = {Baranwal, Gaurav and Mukhtar, Haseeb and Kane, Jamie and Lemieux, Alaura and Misra, Sanjay},
title = {Advancements in Mesenchymal Stem Cell-Based Therapy for Enhancing Arteriovenous Fistula Patency},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252312719}
}
EUVIMED